US EditionSK Life Science Labs Unveils Promising Cancer Research at AACR Annual Meeting
- On April 28, 2025, at the AACR meeting in King of Prussia, Pa., SK Life Science Labs—operating under SK Biopharmaceuticals—unveiled research on novel p300-selective degraders with potential applications in treating prostate cancer and other malignancies involving CBP protein alterations.
- This research builds on SK Group's focus on biopharmaceutical innovation and uses heterobifunctional degraders to target the p300 protein, which is essential for cancer cell survival.
- The degraders demonstrated high potency, once-daily oral administration, rapid p300 degradation, and significant tumor growth inhibition in tumor-bearing mice, particularly in difficult-to-treat prostate and CBP-mutated cancers.
- Ryan Kruger, Ph.D., who leads scientific research at SK Life Science Labs, highlighted that targeting p300 with selective degraders can quickly inhibit tumor progression in difficult cancers while minimizing side effects through precise action, providing optimism for the creation of safer cancer treatments.
- This breakthrough demonstrates SK Life Science Labs' innovative protein degradation strategy, offering promising new treatment options that could improve safety and effectiveness for hard-to-treat cancer types with limited therapies available.
31 Articles
31 Articles
Bennington Banner
Late-Breaking Research from SK Life Science Labs at AACR Annual Meeting Shows p300-Selective Degraders are Potent Growth Inhibitors in Models of Aggressive Prostate Cancers and Solid Tumors
KING OF PRUSSIA, Pa., April 28, 2025 /PRNewswire/ -- SK Life Science Labs, a subsidiary of SK Biopharmaceuticals Co., Ltd., a global biotech focused on the research, development, and commercialization of treatments for disorders of the central nervous system (CNS)…
SK Life Science Labs Unveils Promising Cancer Research at AACR Annual Meeting
KING OF PRUSSIA, PA — SK Life Science Labs, a subsidiary of SK Biopharmaceuticals Co., Ltd., has presented groundbreaking research at the American Association for Cancer Research (AACR) Annual Meeting 2025 in Chicago. Their findings highlight the potential of novel orally bioavailable p300-selective degraders to treat challenging cancers, including prostate cancer and those with CBP protein deficiencies or mutations. The p300 protein plays a cri…
Coverage Details
Bias Distribution
- 36% of the sources are Center, 36% of the sources lean Right
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
